

# LANREOTIDE

BRAND NAME	SOMATULINE AUTOGEL
DRUG CLASS	Somatostatin analogue
AVAILABILITY	Prefilled syringe contains 60 mg/0.5 mL, 90 mg/0.5 mL or 120 mg/0.5 mL of lanreotide as lanreotide acetate as a prolonged-release depot suspension. Also contains glacial acetic acid. <sup>1</sup>
pH	6.1 <sup>1</sup>
PREPARATION	Ready to use. Allow 30 minutes to reach room temperature. <sup>2</sup>
STABILITY	Store at 2 to 8 °C. Do not freeze. <sup>1</sup> Stable for up to three temperature excursions for a total of 24 hours below 40 °C. <sup>1</sup>
ADMINISTRATION	
<b>IM injection</b>	Not recommended
<b>SUBCUT injection</b>	Inject deep into subcutaneous tissue in the superior external quadrant of the buttock. <sup>1</sup> Do not pinch or fold the skin. Insert the needle perpendicular to the skin and to its full length. Alternate between the right and left sides. <sup>1,2</sup> Suitable for self-administration after appropriate patient education. Inject into the upper outer thigh. <sup>1</sup>
<b>IV injection</b>	Not recommended <sup>1</sup>
<b>IV infusion</b>	Not recommended <sup>1</sup>
COMPATIBILITY	Do not mix with fluids or other medicines <sup>1</sup>
INCOMPATIBILITY	No information
SPECIAL NOTES	Lanreotide inhibits the secretion of insulin and glucagon. Monitor blood glucose levels at the start of therapy and when the dose is altered. Patients who use insulin may need to have their insulin dose adjusted. <sup>1</sup>

## REFERENCES

1. Product information. Available from [www.tga.gov.au](http://www.tga.gov.au). Accessed 20/05/2022.
2. Consumer medicine information. Available from [www.tga.gov.au](http://www.tga.gov.au). Accessed 24/06/2022.